1KA.F GH RESEARCH PLC DL-025
- Market cap
- EUR 1.18B
- P/E
- -
- P/B
- 3.69x
- ROE
- -19.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 1KA.F undervalued?
Graham numberThe Graham number of GH RESEARCH PLC DL-025 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
GH RESEARCH PLC DL-025 fundamental analysis
No fundamental analysis for GH RESEARCH PLC DL-025 yet.
GH RESEARCH PLC DL-025 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebu…
Full company profileGH RESEARCH PLC DL-025 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
GH RESEARCH PLC DL-025 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.1M | -30.7M | -41.2M | -50.2M | -60.7M | -76.4M |
| EBITDA | - | -22.4M | -35.2M | -38.6M | -47.9M | -67.8M |
| Net Income | -9.20M | -22.5M | -35.6M | -39.0M | -48.3M | -68.2M |
| EPS | -0.18 | -0.43 | -0.68 | -0.75 | -0.78 | -0.99 |
| Balance Sheet | ||||||
| Total Assets | 280M | 254M | 226M | 188M | 288M | 372M |
| Total Liabilities | 2.75M | 4.55M | 7.33M | 9.32M | 8.53M | 12.9M |
| Shareholders' Equity | 277M | 250M | 219M | 179M | 280M | 359M |
| Cash & Short-term Investments | 277M | 166M | 78.4M | 101M | 246M | 345M |
| Cash Flow | ||||||
| Operating Cash Flow | -15.3M | -26.2M | -33.3M | -42.3M | -43.6M | -51.4M |
| Capital Expenditure | 104K | 67.0K | 100K | 49.0K | 121K | 160K |
| Free Cash Flow | -15.4M | -26.3M | -33.4M | -42.3M | -43.7M | -51.5M |
| Ratios | ||||||
| ROE | -3.3% | -9.0% | -16.3% | -21.8% | -17.3% | -19.0% |
| ROA | -3.3% | -8.8% | -15.7% | -20.7% | -16.7% | -18.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
GH RESEARCH PLC DL-025 dividends
GH RESEARCH PLC DL-025 has not paid dividends in the last 5 fiscal years.
Who owns GH RESEARCH PLC DL-025
- Insiders 24.46%
- Institutions 72.37%
- Public & others 3.18%
- Shares outstanding 68.6M
- Free float 32.4M
GH RESEARCH PLC DL-025 company profile
- Company name
- GH RESEARCH PLC DL-025
- Ticker
- 1KA.F
- ISIN
- IE000GID8VI0
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 73
- Fiscal year end
- December
- Address
- Joshua Dawson House, Dublin, Ireland, D02 RY95
- Phone
- 353 1 437 8334
- Website
- ghres.com
About GH RESEARCH PLC DL-025
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
GH RESEARCH PLC DL-025 management
5- Mr. Florian Schonharting M.Sc. (Econ)Co-Founder & Non-Executive Chairman of the Board · born 1969
- Dr. Velichka Valcheva M.D., M.Sc.Chief Executive Officer · born 1975
- Mr. Magnus HalleCo-Founder & MD of Ireland · born 1997
- Ms. Julie Ryan F.C.A.Vice President of Finance · born 1986
- Mr. Aaron Cameron M.B.A.Chief Operating Officer · born 1985